Ergebnis der Suchanfrage nach Celle
Newsrooms
Inhalte
- Kategorie:
- Sprache:
- Medien:
- Zeitraum:
- Zeitraum:Gesamt
- mehr
Cancer Cachexia: Liver Identified as Driver of Body Wasting
Many people with cancer experience dramatic loss of muscle and fat tissue. In many cases, even the heart muscle is affected, which further weakens the body. This wasting syndrome, known as cachexia, affects around half of all cancer patients. It is a major cause of therapy resistance, complications, and increased mortality. ...
mehr- 5
GEA opens New Food technology center in the U.S. to boost alternative proteins’ scale-up
mehr - 2
New Label-Free Imaging Tracks Cancer Treatment in Single Cells
mehr Ichnos Glenmark Innovation (IGI) and AbbVie Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific Antibody
New York and North Chicago, Ill. (ots/PRNewswire) - - ISB 2001 is currently in Phase 1 clinical trial in patients with relapsed/refractory multiple myeloma (R/R MM) IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation, Inc. (IGI), and AbbVie (NYSE: ABBV) today announced an ...
mehrFraunhofer-Institut für Produktionstechnologie IPT
Transforming personalized medicine with AI-driven CAR-T manufacturing: Automated CAR-T cell production platform is ready for production
mehr
LONGi Green Energy Technology Co., Ltd.
What solar efficiency records mean for homeowners - A glance at the future of solar with Back Contact and Tandem technology
mehr- 3
PM: DHL, Daimler Truck und hylane schließen Partnerschaft bei vollelektrischen Lkw / PR: DHL, Daimler Truck, and hylane form partnership for fully electric trucks
mehr ARPA EMC and Adaptive Balancing Power Join Forces for Cutting-Edge Green Energy Solutions in Critical Infrastructure
Ein Dokumentmehr- 3
Key technology for bioprocesses
mehr ASP Isotopes and Isotopia Announce Supply Agreement for Gadolinium-160 to Accelerate Terbium-161 Production for Advanced Cancer Therapies
Petach Tikva, Israel (ots/PRNewswire) - ASP Isotopes Inc. (NASDAQ: ASPI) and Isotopia Molecular Imaging Ltd. have entered into a strategic agreement to secure the supply of Gadolinium-160 (Gd-160), a critical precursor isotope for producing Terbium-161 (Tb-161), an emerging medical isotope with significant potential ...
mehrNew Microscope Brings Glowing Cells into Focus
mehr
LONGi Green Energy Technology Co., Ltd.
11World-leading solar tech available for private homes / Longi brings high-efficiency module series EcoLife to homeowners
mehrTechnische Universität München
TUM professor develops AI chip
TECHNICAL UNIVERSITY OF MUNICH NEWS RELEASE Cyber-secure and energy-saving AI chip developed for decentralized use without the cloud A new AI chip developed at the Technical University of Munich (TUM) works without the cloud server or internet connections needed by existing chips. The AI Pro, designed by Prof Hussam Amrouch, is modelled on the human brain. Its innovative neuromorphic architecture enables it to perform calculations on the spot, ensuring full cyber security. ...
mehr- 4
PM: Strategische Erweiterung: DHL macht DHL Health Logistics Campus in Florstadt im Rahmen seiner Milliarden-Investitionen zum Pharma-Drehkreuz Europas / PR: Strategic expansion: DHL transforms DHL Health Logistics campus in Florstadt into a European
mehr NeutroFlow: Leading European Medical Consortium Awarded €2.5 Million Grant from EIC Transition Programme to Advance Predictive Biomarker Development for Immunotherapy Response
Heidelberg, Germany, Milan, Seville, Spain and Binyamina, Israel (ots/PRNewswire) - A European-led consortium comprising Heidelberg University Hospital (UKHD), the European Institute of Oncology (IEO), Virgen Macarena University Hospital, and OncoHost today announced that it has been awarded a €2.5 million grant ...
mehr- 2
Press release: Leading global selenium producer RETORTE secures growth in future markets with new facility
Ein Dokumentmehr Biomay Launches FDA-Grade CRISPR/Cas9 Nuclease for Off-the-Shelf Purchase
Vienna, Austria (ots) - Biomay, a leading manufacturer of recombinant proteins, today announced the commercial availability of its CRISPR/Cas9 nuclease, marking a significant addition to its off-the-shelf product portfolio for genome-editing applications. Clients purchasing Biomay´s Cas9 will benefit from the company´s unparalleled track record and expertise as a ...
mehr
HYXiPOWER Goes Beyond with Automotive-Grade Safety at Intersolar 2025
mehrAeson Power Showcases Innovative Sodium Battery Technology at EES Europe 2025
mehrLG Energy Solution Showcases ESS Leadership at ees Europe 2025 in Munich
mehr- 2
Fixed milking times, clear processes: Batch milking with the GEA DairyRobot R9600 series
2 Dokumentemehr IPS Unveils EXERON X-BESS 8 - A Breakthrough in Utility-Scale Battery Energy Storage
mehrPM: DHL Group startet mit Umsatz- und Ergebniswachstum in das Jahr 2025 / PR: DHL Group starts 2025 with revenue and earnings growth
DHL Group startet mit Umsatz- und Ergebniswachstum in das Jahr 2025 - Konzernumsatz hat um 2,8 % auf 20.809 Millionen Euro zugelegt (Q1 2024: 20.251 Millionen Euro) - EBIT um 4,5 % auf 1.370 Millionen Euro (Q1 2024: 1.311 Millionen Euro) gestiegen - ...
4 Dokumentemehr
Biomay Obtains FDA Approval for Manufacturing of Cas9 Nuclease at Headquarters Site
mehrAcousia Therapeutics Reaches 50% Patient Enrollment Milestone in Phase 2 PROHEAR Study
Tübingen, Germany (ots) - Acousia Therapeutics GmbH announced that it has successfully enrolled 50% of patients in its ongoing Phase 2 clinical trial, the PROHEAR Study, evaluating ACOU085 (INN: bimokalner) for the prevention of cisplatin-induced hearing loss in patients with testicular cancer undergoing chemotherapy. Cisplatin is a cornerstone in modern oncology and ...
mehrFeedgy at Intersolar: Powering the future of agriculture and energy at Intersolar
mehrDJI Enterprise Presents Advanced Drone Solutions for Every Stage of the Solar Project Lifecycle at Intersolar Europe
mehrEngineering Smart Delivery for Gene Editors
mehrImmunity Pharma Presents New Data Supporting the Efficacy of IPL344 in ALS
Jerusalem (ots/PRNewswire) - - Results from phase 2a trial in ALS patients were published in Muscle and Nerve. - Statistically significant 58% to 64% slower ALSFRS-R progression rate in IPL344-treated patients compared to the matched PRO-ACT records. - NfL was reduced by 27% for patients treated for at least two months. - Unadjusted median survival for participants in ...
mehr